Hyperlipidemia Flashcards Preview

Pharma A > Hyperlipidemia > Flashcards

Flashcards in Hyperlipidemia Deck (28)
Loading flashcards...
1
Q

MoA of Statin

A

Inhibit HMGCoA

2
Q

Rate limiting enzyme in hepatic cholesterol synthesis

A

HMG-CoA

3
Q

Primary clinical effects of statin

A

Reduce LDL and TAG

Increase HDL

4
Q

What are the other beneficial effects of statin

A
Inhibit monocyte migration and adhesion to endothelium
Monocyte proliferation
Oxidation of LDL
Immune and inflam
Stabilize atherosclerotic plaque
5
Q

What statin drugs are metabolized by the CYP3A4

A

Simvastatin
Atorvastatin
Lovastatin

6
Q

How is pravastatin metabolized

A

Glucoronidation

7
Q

This AE primarily occurs at high dose of statin

A

Rhabdomyolysis

8
Q

What statin has a fewer effect on the muscle

A

Pravastatin

9
Q

What can inhibit CYP2A9

A

Warfarin

10
Q

This inhibits the OATP3 transporter

A

Gemfibrozil

11
Q

Considered as a second line and adjunct treatment

A

Bile acid binding resins

12
Q

MoA of bile acid resins

A

Up regulation of cholesterol 7 a hydrolase

13
Q

Downside of bile resin

A

Can generate vldl and tag in px with type 3 dyslipoproteinemia

14
Q

Therapeutic use of bile acid resin

A

Primary hyperlipidemia young

Pruritus

Children and pregnant

15
Q

AE of BaR

A

Constipation
Bloating
Flatulence

No ADEK except colesevelam

16
Q

Cholesterol inhibitor

A

Ezetimibe

17
Q

MoA of ezetimibe

A

Inhibits NPC1L1

Absorption of both dietary and biliary cholesterol

18
Q

Common AE of ezetimibe

A

Flatulence

19
Q

What drug can increase ezetimibe concentration

A

Cyclosporin

20
Q

What is the only drug can significantly reduce lpA

A

Niacin

21
Q

Most effective agent that can increase HDL

A

Niacin

22
Q

AE of niacin

A

Skin flushing, pruritis and sensation of warmth

23
Q

What is given sensation of warmth in niacin

A

Aspirin

Ibuprofen

24
Q

They act as a ligand to PPAR

A

Fibrates

Fenofibrate
Gemfibrozil

25
Q

MoA of fibrate

A

Lipase in muscle

Apolipoprotein C3

26
Q

AE of chronic use of fibrates

A

Gallstone formation

27
Q

PCSK9 inhibitors

A

Alirocumab

Evolucumab

28
Q

MoA of PCSK9

A

Reduced LDL receptors